Document_And_Entity_Informatio
Document And Entity Information | 6 Months Ended | |
Nov. 30, 2013 | Jan. 14, 2014 | |
Document and Entity Information [Abstract] | ' | ' |
Entity Registrant Name | 'BIOMERICA INC. | ' |
Document Type | '10-Q | ' |
Current Fiscal Year End Date | '--05-31 | ' |
Entity Common Stock, Shares Outstanding | ' | 7,291,214 |
Amendment Flag | 'false | ' |
Entity Central Index Key | '0000073290 | ' |
Entity Current Reporting Status | 'Yes | ' |
Entity Voluntary Filers | 'No | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Well-known Seasoned Issuer | 'No | ' |
Document Period End Date | 30-Nov-13 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q2 | ' |
CONDENSED_CONSOLIDATED_STATEME
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (UNAUDITED) (USD $) | 3 Months Ended | 6 Months Ended | ||
Nov. 30, 2013 | Nov. 30, 2012 | Nov. 30, 2013 | Nov. 30, 2012 | |
Net sales | $934,841 | $1,883,771 | $1,948,580 | $3,585,719 |
Cost of sales | -679,197 | -1,114,560 | -1,432,645 | -2,084,259 |
Gross profit | 255,644 | 769,211 | 515,935 | 1,501,460 |
Operating Expenses: | ' | ' | ' | ' |
Selling, general and administrative | 366,357 | 405,968 | 709,160 | 738,094 |
Research and development | 136,789 | 115,741 | 228,046 | 203,722 |
Total operating expenses | 503,146 | 521,709 | 937,206 | 941,816 |
(Loss) income from operations | -247,502 | 247,502 | -421,271 | 559,644 |
Other Income (Expense): | ' | ' | ' | ' |
Dividend and interest income | 4,145 | 1,127 | 10,199 | 2,243 |
Interest expense | ' | ' | ' | -308 |
Total other income | 4,145 | 1,127 | 10,199 | 1,935 |
(Loss) income before income tax | -243,357 | 248,629 | -411,072 | 561,579 |
Provision for income taxes | ' | -11,710 | ' | -33,029 |
Net (loss) income | -243,357 | 236,919 | -411,072 | 528,550 |
Basic net (loss) income per common share (in Dollars per share) | ($0.03) | $0.03 | ($0.06) | $0.08 |
Diluted net (loss) income per common share (in Dollars per share) | ($0.03) | $0.03 | ($0.06) | $0.07 |
Weighted average number of common and common equivalent shares: | ' | ' | ' | ' |
Basic (in Shares) | 7,278,967 | 6,966,185 | 7,277,659 | 6,959,224 |
Diluted (in Shares) | 7,278,967 | 7,385,139 | 7,277,659 | 7,282,202 |
Net (loss) income | -243,357 | 236,919 | -411,072 | 528,550 |
Other comprehensive loss, net of tax: | ' | ' | ' | ' |
Foreign currency translation | 77 | -473 | -14 | -554 |
Comprehensive (loss) income | ($243,280) | $236,446 | ($411,086) | $527,996 |
CONDENSED_CONSOLIDATED_BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) | Nov. 30, 2013 | 31-May-13 |
Current Assets: | ' | ' |
Cash and cash equivalents | $1,647,559 | $2,469,796 |
Accounts receivable, less allowance for doubtful accounts of $120,405 and $115,730 as of November 30, 2013 and May 31, 2013, respectively | 821,571 | 871,660 |
Inventories, net | 1,899,633 | 1,571,221 |
Prepaid expenses and other | 186,362 | 196,678 |
Deferred tax assets, current portion | 144,000 | 144,000 |
Total current assets | 4,699,125 | 5,253,355 |
Property and Equipment, net of accumulated depreciation and amortization of $1,118,240 and $1,032,009 as of November 30, 2013 and May 31, 2013, respectively | 652,244 | 654,620 |
Deferred Tax Assets, net of current portion | 85,000 | 85,000 |
Investments | 165,324 | 165,324 |
Intangible Assets, net | 154,079 | 165,200 |
Other Assets | 71,388 | 71,388 |
Total Assets | 5,827,160 | 6,394,887 |
Current Liabilities: | ' | ' |
Accounts payable and accrued expenses | 279,974 | 351,917 |
Accrued compensation | 120,618 | 207,976 |
Total current liabilities | 400,592 | 559,893 |
Commitments and Contingencies (Note 5) | ' | ' |
Shareholders' Equity: | ' | ' |
Preferred stock, no par value authorized 5,000,000 shares, none issued and none outstanding at November 30, 2013 and May 31, 2013 | ' | ' |
Common stock, $0.08 par value authorized 25,000,000 shares, issued and outstanding 7,279,214 and 7,274,714 at November 30 and May 31, 2013, respectively | 582,336 | 581,976 |
Additional paid-in-capital | 18,036,696 | 18,034,396 |
Accumulated other comprehensive loss | -9,020 | -9,006 |
Accumulated deficit | -13,183,444 | -12,772,372 |
Total Shareholders' Equity | 5,426,568 | 5,834,994 |
Total Liabilities and Shareholders' Equity | $5,827,160 | $6,394,887 |
CONDENSED_CONSOLIDATED_BALANCE1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $) | Nov. 30, 2013 | 31-May-13 |
Allowance for doubtful accounts (in Dollars) | $120,405 | $115,730 |
Accumulated depreciation and amortization (in Dollars) | $1,118,240 | $1,032,009 |
Preferred stock, Shares authorized (in Shares) | 5,000,000 | 5,000,000 |
Preferred stock, Shares Issued (in Shares) | 0 | 0 |
Preferred stock, Shares Outstanding (in Shares) | 0 | 0 |
Preferred stock, No Par Value (in Dollars per share) | ' | ' |
Common stock, Par Value (in Dollars per share) | $0.08 | $0.08 |
Common stock, Shares Authorized (in Shares) | 25,000,000 | 25,000,000 |
Common stock, Shares Issued (in Shares) | 7,279,214 | 7,274,714 |
Common stock, Shares Outstanding (in Shares) | 7,279,214 | 7,274,714 |
CONDENSED_CONSOLIDATED_STATEME1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) | 6 Months Ended | |
Nov. 30, 2013 | Nov. 30, 2012 | |
Cash flows from operating activities: | ' | ' |
Net (loss) income | ($411,072) | $528,550 |
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ' | ' |
Depreciation and amortization | 97,352 | 110,822 |
Stock option expense | 881 | ' |
Change in provision for losses on accounts receivable | 4,675 | 4,210 |
Inventory reserve | -6,713 | 2,047 |
Decrease in deferred rent liability | -6,418 | -1,764 |
Changes in assets and liabilities: | ' | ' |
Accounts receivable | 45,414 | -313,358 |
Inventories | -321,700 | 18,921 |
Prepaid expenses and other assets | 10,316 | 49,413 |
Accounts payable and other accrued expenses | -65,525 | -27,461 |
Accrued compensation | -87,358 | 25,618 |
Net cash (used in) provided by operating activities | -740,148 | 396,998 |
Cash flows from investing activities: | ' | ' |
Purchases of property and equipment | -83,855 | -242,416 |
Net cash used in investing activities | -83,855 | -242,416 |
Cash flows from financing activities: | ' | ' |
Proceeds from exercise of stock options | 1,780 | 5,999 |
Payments on line of credit or equipment loan | ' | -43,000 |
Net cash provided by (used in) financing activities | 1,780 | -37,001 |
Effect of exchange rate changes in cash | -14 | -554 |
Net (decrease) increase in cash and cash equivalents | -822,237 | 117,027 |
Cash and cash equivalents at beginning of period | 2,469,796 | 1,077,342 |
Cash and cash equivalents at end of period | 1,647,559 | 1,194,369 |
Supplemental Disclosure of Cash-Flow Information: | ' | ' |
Interest | ' | 307 |
Income taxes | $3,500 | $108,160 |
Basis_of_Presentation
Basis of Presentation | 6 Months Ended |
Nov. 30, 2013 | |
Disclosure Text Block [Abstract] | ' |
Basis of Accounting [Text Block] | ' |
Note 1: Basis of Presentation | |
The information set forth in these condensed consolidated financial statements is unaudited and reflects all adjustments which, in the opinion of management, are necessary to present a fair statement of the consolidated results of operations of Biomerica, Inc. and subsidiaries (the “Company”), for the periods indicated. It does not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with generally accepted accounting principles. All adjustments that were made are of normal recurring nature. | |
The unaudited Condensed Consolidated Financial Statements and Notes are presented as permitted by the requirements for Form 10-Q and do not contain certain information included in our annual financial statements and notes. The condensed consolidated balance sheet data as of May 31, 2013 was derived from audited financial statements. The accompanying interim condensed consolidated financial statements should be read in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on November 30, 2013 for the fiscal year ended May 31, 2013. The results of operations for our interim periods are not necessarily indicative of results to be achieved for our full fiscal year. |
Significant_Accounting_Policie
Significant Accounting Policies | 6 Months Ended | ||||||||||||
Nov. 30, 2013 | |||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||
Significant Accounting Policies [Text Block] | ' | ||||||||||||
Note 2: Significant Accounting Policies | |||||||||||||
Principles of Consolidation | |||||||||||||
The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as the Company’s German subsidiary and Mexican subsidiary which have not begun operations. All significant intercompany accounts and transactions have been eliminated in consolidation. | |||||||||||||
Accounting Estimates | |||||||||||||
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reported period. Actual results could materially differ from those estimates. | |||||||||||||
Cash and Cash Equivalents | |||||||||||||
Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months. | |||||||||||||
Accounts Receivable | |||||||||||||
The Company extends unsecured credit to its customers on a regular basis. International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Credit levels are approved by designated upper level management. Domestic customers are extended initial credit limits until they establish a history with the Company or submit credit information. All increases in credit limits are also approved by designated upper level management. Management evaluates receivables on a quarterly basis and adjusts the reserve for bad debt accordingly. Balances over ninety days old are reserved for unless collection is reasonably assured. Management evaluates quarterly what items to charge off. Any charge-offs are approved by upper level management prior to charging off. | |||||||||||||
Occasionally certain long-standing customers, who routinely place large orders, will have unusually large accounts receivables balances relative to the total gross accounts receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders. | |||||||||||||
Inventories | |||||||||||||
The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or market. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the Company’s production facilities. | |||||||||||||
The approximate balances of inventories are the following at: | |||||||||||||
November 30, | May | ||||||||||||
31, | |||||||||||||
2013 | 2013 | ||||||||||||
Raw materials | $ | 864,000 | $ | 787,000 | |||||||||
Work in progress | 755,000 | 555,000 | |||||||||||
Finished products | 281,000 | 229,000 | |||||||||||
Total | $ | 1,900,000 | $ | 1,571,000 | |||||||||
Property and Equipment | |||||||||||||
Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation or amortization is removed from the accounts, and gains or losses from retirements and dispositions are credited or charged to income. | |||||||||||||
Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment and leasehold improvements amounted to $43,452 and $65,435 for the three months ended November 30, 2013 and 2012, and $86,231 and $93,263 for the six months ended November 30, 2013 and 2012, respectively. | |||||||||||||
Intangible Assets | |||||||||||||
Intangible assets include trademarks, product rights, licenses, technology rights and patents, and are accounted for based on Accounting Standards Codification ASC 350 “Intangibles – Goodwill and Other” (ASC 350). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life; not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, licenses, and 17 years for patents. Amortization amounted to $3,665 and $8,779 for the three months ended November 30, 2013 and 2012, respectively, and $11,121 and $17,559 for the six months ended November 30, 2013 and 2012, respectively. | |||||||||||||
Stock-Based Compensation | |||||||||||||
The Company follows the guidance of the accounting provisions of ASC 718 “Share-based Compensation” (ASC 718), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The fair value of each option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. | |||||||||||||
Expected volatilities are based on weighted averages of the historical volatility of the Company’s stock and other factors estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. | |||||||||||||
The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of November 30, 2013: | |||||||||||||
Option Shares | Exercise Price Weighted Average | ||||||||||||
Outstanding May 31, 2013 | 846,500 | $ | 0.47 | ||||||||||
Granted | 52,000 | $ | 0.84 | ||||||||||
Exercised | -4,500 | $ | 0.4 | ||||||||||
Cancelled or expired | -10,000 | $ | 0.43 | ||||||||||
Outstanding November 30, 2013 | 884,000 | $ | 0.49 | ||||||||||
On June 10, 2013, the Board granted a stock option to purchase 20,000 shares of the Company’s common stock at the purchase price of $0.83 per share. | |||||||||||||
On November 13, 2013, the Board granted stock options to purchase 32,000 shares of the Company’s common stock at the purchase price of $0.84 per share. | |||||||||||||
In June 2013, options to exercise 2,000 shares of the Company’s common stock were exercised at the exercise price of $0.38 per share. Net proceeds to the Company were $760. | |||||||||||||
In September 2013, options to exercise 2,500 shares of the Company’s common stock were exercised at the exercise prices of $0.45 and $0.38 per share. | |||||||||||||
In December 2013, options to exercise 12,000 shares of the Company’s common stock were exercised at the exercise price of $0.38 per share. | |||||||||||||
Revenue Recognition | |||||||||||||
Revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, at which point title passes. An allowance is established when necessary for estimated returns as revenue is recognized. In conjunction with sales to certain customers, the Company provides free products upon attaining certain levels of purchases by the customer. The Company accounts for these free products in accordance with ASC 605-50 “Revenue Recognition – Customer Payments and Incentives” and recognizes the cost of the product as part of cost of sales. | |||||||||||||
Investments | |||||||||||||
From time-to-time, the Company makes investments in privately-held companies. The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value to be less than the fair value. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical devices. The Company owns approximately 6% of the investee, and accordingly, applies the cost method to account for the investment. Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received. | |||||||||||||
Shipping and Handling Fees and Costs | |||||||||||||
Shipping and handling fees billed to customers are classified as revenues, and shipping and handling costs are classified as cost of sales. The Company included shipping and handling fees billed to customers in net sales. The Company included shipping and handling costs associated with inbound freight and unreimbursed shipping to customers in cost of sales. | |||||||||||||
Research and Development | |||||||||||||
Research and development costs are expensed as incurred. | |||||||||||||
Income Taxes | |||||||||||||
The Company has provided a valuation allowance of $0 as of November 30, 2013 and May 31, 2013. In May 2013, after analyzing the Company’s tax position, operational history and profitability for the past 3 years, management chose to remove all of the remaining allowance for the uncertainty of its future income, as the determination that it was more likely that the deferred tax asset would be realized in the future. | |||||||||||||
Foreign Currency Translation | |||||||||||||
The subsidiary located in Germany is accounted for primarily using local functional currency. Accordingly, assets and liabilities of this subsidiary are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting adjustments are presented as a separate component of accumulated other comprehensive loss. | |||||||||||||
Deferred Rent | |||||||||||||
Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability is amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. | |||||||||||||
Net Income (Loss) Per Share | |||||||||||||
Basic earnings (loss) per share are computed as net income (loss) divided by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflect the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities. The total amount of anti-dilutive warrants or options not included in the earnings (loss) per share calculation for the three and six months ended November 30, 2013 was 372,816 and 379,180, respectively. There were no anti-dilutive warrants or options excluded from the earnings per share calculation for the three and six months ended November 30, 2012. | |||||||||||||
The following table illustrates the required disclosure of the reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. | |||||||||||||
Three Months Ended | |||||||||||||
Six Months Ended | |||||||||||||
November 30, | |||||||||||||
November 30, | |||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||
Numerator: | |||||||||||||
(Loss)income from continuing operations | $ | -411,072 | $ | 528,550 | $ | -243,357 | $ | 236,919 | |||||
Denominator for basic net (loss) income | 7,277,659 | 6,959,224 | 7,278,967 | 6,966,185 | |||||||||
Per common share | |||||||||||||
Effect of dilutive securities: | |||||||||||||
Options and warrants | - | 322,978 | - | 418,954 | |||||||||
Denominator for diluted net (loss) income | 7,277,659 | 7,282,202 | 7,278,967 | 7,385,139 | |||||||||
per common share | |||||||||||||
Basic net (loss) income per common share | $ | -0.06 | $ | 0.08 | $ | -0.03 | $ | 0.03 | |||||
Diluted net (loss) income per common share | $ | -0.06 | $ | 0.07 | $ | -0.03 | $ | 0.03 | |||||
New Accounting Pronouncements | |||||||||||||
Management does not believe that any recently issued, but not effective, accounting standards if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. |
Accounts_Payable_and_Accrued_E
Accounts Payable and Accrued Expenses | 6 Months Ended | ||||||
Nov. 30, 2013 | |||||||
Payables and Accruals [Abstract] | ' | ||||||
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | ' | ||||||
Note 3: Accounts Payable and Accrued Expenses | |||||||
The Company’s accounts payable and accrued expense balances consist of the following at: | |||||||
November 30, | May | ||||||
31, | |||||||
2013 | 2013 | ||||||
Accounts payable | $ | 167,810 | $ | 282,138 | |||
Accrued expenses | 48,803 | - | |||||
Deferred rent | 63,361 | 69,779 | |||||
Total | $ | 279,974 | $ | 351,917 | |||
Geographic_Information
Geographic Information | 6 Months Ended | ||||||||||||
Nov. 30, 2013 | |||||||||||||
Geographic Information Disclosure [Abstract] | ' | ||||||||||||
Geographic Information Disclosure [Text Block] | ' | ||||||||||||
Note 4: Geographic Information | |||||||||||||
Financial information about foreign and domestic operations and export sales approximated as follows: | |||||||||||||
Six Months Ended | Three Months Ended | ||||||||||||
November 30, | November 30, | ||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||
Revenues from sales to unaffiliated customers: | |||||||||||||
United States | $ | 505,000 | $ | 437,000 | $ | 251,000 | $ | 157,000 | |||||
Asia | 216,000 | 1,944,000 | 80,000 | 1,042,000 | |||||||||
Europe | 1,199,000 | 1,183,000 | 594,000 | 675,000 | |||||||||
South America | 7,000 | 2,000 | 4,000 | 2,000 | |||||||||
Middle East | 20,000 | 18,000 | 5,000 | 7,000 | |||||||||
Other | 2,000 | 2,000 | 1,000 | 1,000 | |||||||||
Total | $ | 1,949,000 | $ | 3,586,000 | $ | 935,000 | $ | 1,884,000 | |||||
No other geographic concentrations exist where net sales exceed 10% of total net sales. |
Commitments_and_Contingencies
Commitments and Contingencies | 6 Months Ended |
Nov. 30, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments and Contingencies Disclosure [Text Block] | ' |
Note 5: Commitments and Contingencies | |
On February 13, 2009, the Company renewed the line of credit (the "Line") with its bank which has a borrowing limit of $400,000. The Line is secured by substantially all of the Company’s assets, bears interest at 1.0% plus the Wall Street Journal Prime West Coast Edition prime rate and expires February 24, 2014. The balance at November 30, 2013 and May 31, 2013 was $0. | |
On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ends August 31, 2016. The initial base rent was set at $18,490 per month with scheduled annual increases through the end of the lease term. The rent is currently set at $20,810 per month. |
Accounting_Policies_by_Policy_
Accounting Policies, by Policy (Policies) | 6 Months Ended | ||||||||||||
Nov. 30, 2013 | |||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||
Consolidation, Policy [Policy Text Block] | ' | ||||||||||||
Principles of Consolidation | |||||||||||||
The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as the Company’s German subsidiary and Mexican subsidiary which have not begun operations. All significant intercompany accounts and transactions have been eliminated in consolidation. | |||||||||||||
Use of Estimates, Policy [Policy Text Block] | ' | ||||||||||||
Accounting Estimates | |||||||||||||
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reported period. Actual results could materially differ from those estimates. | |||||||||||||
Cash and Cash Equivalents, Policy [Policy Text Block] | ' | ||||||||||||
Cash and Cash Equivalents | |||||||||||||
Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months. | |||||||||||||
Trade and Other Accounts Receivable, Policy [Policy Text Block] | ' | ||||||||||||
Accounts Receivable | |||||||||||||
The Company extends unsecured credit to its customers on a regular basis. International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Credit levels are approved by designated upper level management. Domestic customers are extended initial credit limits until they establish a history with the Company or submit credit information. All increases in credit limits are also approved by designated upper level management. Management evaluates receivables on a quarterly basis and adjusts the reserve for bad debt accordingly. Balances over ninety days old are reserved for unless collection is reasonably assured. Management evaluates quarterly what items to charge off. Any charge-offs are approved by upper level management prior to charging off. | |||||||||||||
Occasionally certain long-standing customers, who routinely place large orders, will have unusually large accounts receivables balances relative to the total gross accounts receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders. | |||||||||||||
Inventory, Policy [Policy Text Block] | ' | ||||||||||||
Inventories | |||||||||||||
The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or market. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the Company’s production facilities. | |||||||||||||
The approximate balances of inventories are the following at: | |||||||||||||
November 30, | May | ||||||||||||
31, | |||||||||||||
2013 | 2013 | ||||||||||||
Raw materials | $ | 864,000 | $ | 787,000 | |||||||||
Work in progress | 755,000 | 555,000 | |||||||||||
Finished products | 281,000 | 229,000 | |||||||||||
Total | $ | 1,900,000 | $ | 1,571,000 | |||||||||
Property, Plant and Equipment, Policy [Policy Text Block] | ' | ||||||||||||
Property and Equipment | |||||||||||||
Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation or amortization is removed from the accounts, and gains or losses from retirements and dispositions are credited or charged to income. | |||||||||||||
Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment and leasehold improvements amounted to $43,452 and $65,435 for the three months ended November 30, 2013 and 2012, and $86,231 and $93,263 for the six months ended November 30, 2013 and 2012, respectively. | |||||||||||||
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] | ' | ||||||||||||
Intangible Assets | |||||||||||||
Intangible assets include trademarks, product rights, licenses, technology rights and patents, and are accounted for based on Accounting Standards Codification ASC 350 “Intangibles – Goodwill and Other” (ASC 350). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life; not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, licenses, and 17 years for patents. Amortization amounted to $3,665 and $8,779 for the three months ended November 30, 2013 and 2012, respectively, and $11,121 and $17,559 for the six months ended November 30, 2013 and 2012, respectively. | |||||||||||||
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | ' | ||||||||||||
Stock-Based Compensation | |||||||||||||
The Company follows the guidance of the accounting provisions of ASC 718 “Share-based Compensation” (ASC 718), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The fair value of each option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. | |||||||||||||
Expected volatilities are based on weighted averages of the historical volatility of the Company’s stock and other factors estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. | |||||||||||||
The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of November 30, 2013: | |||||||||||||
Option Shares | Exercise Price Weighted Average | ||||||||||||
Outstanding May 31, 2013 | 846,500 | $ | 0.47 | ||||||||||
Granted | 52,000 | $ | 0.84 | ||||||||||
Exercised | -4,500 | $ | 0.4 | ||||||||||
Cancelled or expired | -10,000 | $ | 0.43 | ||||||||||
Outstanding November 30, 2013 | 884,000 | $ | 0.49 | ||||||||||
On June 10, 2013, the Board granted a stock option to purchase 20,000 shares of the Company’s common stock at the purchase price of $0.83 per share. | |||||||||||||
On November 13, 2013, the Board granted stock options to purchase 32,000 shares of the Company’s common stock at the purchase price of $0.84 per share. | |||||||||||||
In June 2013, options to exercise 2,000 shares of the Company’s common stock were exercised at the exercise price of $0.38 per share. Net proceeds to the Company were $760. | |||||||||||||
In September 2013, options to exercise 2,500 shares of the Company’s common stock were exercised at the exercise prices of $0.45 and $0.38 per share. | |||||||||||||
In December 2013, options to exercise 12,000 shares of the Company’s common stock were exercised at the exercise price of $0.38 per share. | |||||||||||||
Revenue Recognition, Policy [Policy Text Block] | ' | ||||||||||||
Revenue Recognition | |||||||||||||
Revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, at which point title passes. An allowance is established when necessary for estimated returns as revenue is recognized. In conjunction with sales to certain customers, the Company provides free products upon attaining certain levels of purchases by the customer. The Company accounts for these free products in accordance with ASC 605-50 “Revenue Recognition – Customer Payments and Incentives” and recognizes the cost of the product as part of cost of sales. | |||||||||||||
Investment, Policy [Policy Text Block] | ' | ||||||||||||
Investments | |||||||||||||
From time-to-time, the Company makes investments in privately-held companies. The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value to be less than the fair value. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical devices. The Company owns approximately 6% of the investee, and accordingly, applies the cost method to account for the investment. Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received. | |||||||||||||
Shipping and Handling Cost, Policy [Policy Text Block] | 'Shipping and Handling Fees and Costs | ||||||||||||
Shipping and handling fees billed to customers are classified as revenues, and shipping and handling costs are classified as cost of sales. The Company included shipping and handling fees billed to customers in net sales. The Company included shipping and handling costs associated with inbound freight and unreimbursed shipping to customers in cost of sales. | |||||||||||||
Research and Development Expense, Policy [Policy Text Block] | ' | ||||||||||||
Research and Development | |||||||||||||
Research and development costs are expensed as incurred. | |||||||||||||
Income Tax, Policy [Policy Text Block] | ' | ||||||||||||
Income Taxes | |||||||||||||
The Company has provided a valuation allowance of $0 as of November 30, 2013 and May 31, 2013. In May 2013, after analyzing the Company’s tax position, operational history and profitability for the past 3 years, management chose to remove all of the remaining allowance for the uncertainty of its future income, as the determination that it was more likely that the deferred tax asset would be realized in the future. | |||||||||||||
Foreign Currency Transactions and Translations Policy [Policy Text Block] | ' | ||||||||||||
Foreign Currency Translation | |||||||||||||
The subsidiary located in Germany is accounted for primarily using local functional currency. Accordingly, assets and liabilities of this subsidiary are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting adjustments are presented as a separate component of accumulated other comprehensive loss. | |||||||||||||
Deferred Charges, Policy [Policy Text Block] | ' | ||||||||||||
Deferred Rent | |||||||||||||
Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability is amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. | |||||||||||||
Earnings Per Share, Policy [Policy Text Block] | ' | ||||||||||||
Net Income (Loss) Per Share | |||||||||||||
Basic earnings (loss) per share are computed as net income (loss) divided by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflect the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities. The total amount of anti-dilutive warrants or options not included in the earnings (loss) per share calculation for the three and six months ended November 30, 2013 was 372,816 and 379,180, respectively. There were no anti-dilutive warrants or options excluded from the earnings per share calculation for the three and six months ended November 30, 2012. | |||||||||||||
The following table illustrates the required disclosure of the reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. | |||||||||||||
Three Months Ended | |||||||||||||
Six Months Ended | |||||||||||||
November 30, | |||||||||||||
November 30, | |||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||
Numerator: | |||||||||||||
(Loss)income from continuing operations | $ | -411,072 | $ | 528,550 | $ | -243,357 | $ | 236,919 | |||||
Denominator for basic net (loss) income | 7,277,659 | 6,959,224 | 7,278,967 | 6,966,185 | |||||||||
Per common share | |||||||||||||
Effect of dilutive securities: | |||||||||||||
Options and warrants | - | 322,978 | - | 418,954 | |||||||||
Denominator for diluted net (loss) income | 7,277,659 | 7,282,202 | 7,278,967 | 7,385,139 | |||||||||
per common share | |||||||||||||
Basic net (loss) income per common share | $ | -0.06 | $ | 0.08 | $ | -0.03 | $ | 0.03 | |||||
Diluted net (loss) income per common share | $ | -0.06 | $ | 0.07 | $ | -0.03 | $ | 0.03 | |||||
New Accounting Pronouncements, Policy [Policy Text Block] | ' | ||||||||||||
New Accounting Pronouncements | |||||||||||||
Management does not believe that any recently issued, but not effective, accounting standards if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. |
Significant_Accounting_Policie1
Significant Accounting Policies (Tables) | 6 Months Ended | ||||||||||||
Nov. 30, 2013 | |||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||
Schedule of Inventory, Current [Table Text Block] | ' | ||||||||||||
November 30, | May | ||||||||||||
31, | |||||||||||||
2013 | 2013 | ||||||||||||
Raw materials | $ | 864,000 | $ | 787,000 | |||||||||
Work in progress | 755,000 | 555,000 | |||||||||||
Finished products | 281,000 | 229,000 | |||||||||||
Total | $ | 1,900,000 | $ | 1,571,000 | |||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | ||||||||||||
Option Shares | Exercise Price Weighted Average | ||||||||||||
Outstanding May 31, 2013 | 846,500 | $ | 0.47 | ||||||||||
Granted | 52,000 | $ | 0.84 | ||||||||||
Exercised | -4,500 | $ | 0.4 | ||||||||||
Cancelled or expired | -10,000 | $ | 0.43 | ||||||||||
Outstanding November 30, 2013 | 884,000 | $ | 0.49 | ||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | ' | ||||||||||||
Three Months Ended | |||||||||||||
Six Months Ended | |||||||||||||
November 30, | |||||||||||||
November 30, | |||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||
Numerator: | |||||||||||||
(Loss)income from continuing operations | $ | -411,072 | $ | 528,550 | $ | -243,357 | $ | 236,919 | |||||
Denominator for basic net (loss) income | 7,277,659 | 6,959,224 | 7,278,967 | 6,966,185 | |||||||||
Per common share | |||||||||||||
Effect of dilutive securities: | |||||||||||||
Options and warrants | - | 322,978 | - | 418,954 | |||||||||
Denominator for diluted net (loss) income | 7,277,659 | 7,282,202 | 7,278,967 | 7,385,139 | |||||||||
per common share | |||||||||||||
Basic net (loss) income per common share | $ | -0.06 | $ | 0.08 | $ | -0.03 | $ | 0.03 | |||||
Diluted net (loss) income per common share | $ | -0.06 | $ | 0.07 | $ | -0.03 | $ | 0.03 |
Accounts_Payable_and_Accrued_E1
Accounts Payable and Accrued Expenses (Tables) | 6 Months Ended | ||||||
Nov. 30, 2013 | |||||||
Payables and Accruals [Abstract] | ' | ||||||
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | ' | ||||||
November 30, | May | ||||||
31, | |||||||
2013 | 2013 | ||||||
Accounts payable | $ | 167,810 | $ | 282,138 | |||
Accrued expenses | 48,803 | - | |||||
Deferred rent | 63,361 | 69,779 | |||||
Total | $ | 279,974 | $ | 351,917 |
Geographic_Information_Tables
Geographic Information (Tables) | 6 Months Ended | ||||||||||||
Nov. 30, 2013 | |||||||||||||
Geographic Information Disclosure [Abstract] | ' | ||||||||||||
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] | ' | ||||||||||||
Six Months Ended | Three Months Ended | ||||||||||||
November 30, | November 30, | ||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||
Revenues from sales to unaffiliated customers: | |||||||||||||
United States | $ | 505,000 | $ | 437,000 | $ | 251,000 | $ | 157,000 | |||||
Asia | 216,000 | 1,944,000 | 80,000 | 1,042,000 | |||||||||
Europe | 1,199,000 | 1,183,000 | 594,000 | 675,000 | |||||||||
South America | 7,000 | 2,000 | 4,000 | 2,000 | |||||||||
Middle East | 20,000 | 18,000 | 5,000 | 7,000 | |||||||||
Other | 2,000 | 2,000 | 1,000 | 1,000 | |||||||||
Total | $ | 1,949,000 | $ | 3,586,000 | $ | 935,000 | $ | 1,884,000 |
Significant_Accounting_Policie2
Significant Accounting Policies (Details) (USD $) | 0 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | ||||||
Nov. 13, 2013 | Jun. 10, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Nov. 30, 2013 | Nov. 30, 2012 | Nov. 30, 2013 | Nov. 30, 2012 | Dec. 31, 2013 | Nov. 30, 2013 | Nov. 30, 2013 | Nov. 30, 2013 | Sep. 30, 2013 | Nov. 30, 2013 | Sep. 30, 2013 | Nov. 30, 2013 | |
Subsequent Event [Member] | Marketing And Distribution Rights [Member] | Purchased Technology Use Rightsand Licenses [Member] | Patents [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | |||||||||
Significant Accounting Policies (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Property, Plant and Equipment, Useful Life | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | '10 years |
Depreciation, Depletion and Amortization (in Dollars) | ' | ' | ' | ' | $43,452 | $65,435 | $86,231 | $93,263 | ' | ' | ' | ' | ' | ' | ' | ' |
Finite-Lived Intangible Asset, Useful Life | ' | ' | ' | ' | ' | ' | ' | ' | ' | '18 years | '10 years | '17 years | ' | ' | ' | ' |
Amortization of Intangible Assets (in Dollars) | ' | ' | ' | ' | 3,665 | 8,779 | 11,121 | 17,559 | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 32,000 | 20,000 | ' | ' | ' | ' | 52,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $0.84 | $0.83 | ' | ' | ' | ' | $0.84 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) | ' | ' | 2,500 | 2,000 | ' | ' | 4,500 | ' | 12,000 | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share) | ' | ' | ' | $0.38 | ' | ' | $0.40 | ' | $0.38 | ' | ' | ' | $0.38 | ' | $0.45 | ' |
Proceeds from Stock Options Exercised (in Dollars) | ' | ' | ' | 760 | ' | ' | 1,780 | 5,999 | ' | ' | ' | ' | ' | ' | ' | ' |
Equity Method Investment, Ownership Percentage | ' | ' | ' | ' | 6.00% | ' | 6.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Deferred Tax Assets, Valuation Allowance (in Dollars) | ' | ' | ' | ' | $0 | ' | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | ' | ' | ' | ' | 372,816 | ' | 379,180 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Significant_Accounting_Policie3
Significant Accounting Policies (Details) - Inventories (USD $) | Nov. 30, 2013 | 31-May-13 |
Inventories [Abstract] | ' | ' |
Raw materials | $864,000 | $787,000 |
Work in progress | 755,000 | 555,000 |
Finished products | 281,000 | 229,000 |
Total | $1,899,633 | $1,571,221 |
Significant_Accounting_Policie4
Significant Accounting Policies (Details) - Options and warrants (USD $) | 0 Months Ended | 1 Months Ended | 6 Months Ended | ||
Nov. 13, 2013 | Jun. 10, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Nov. 30, 2013 | |
Options and warrants [Abstract] | ' | ' | ' | ' | ' |
Outstanding May 31, 2013 | ' | ' | ' | 846,500 | 846,500 |
Outstanding May 31, 2013 (in Dollars per share) | ' | ' | ' | $0.47 | $0.47 |
Granted | 32,000 | 20,000 | ' | ' | 52,000 |
Granted (in Dollars per share) | $0.84 | $0.83 | ' | ' | $0.84 |
Exercised | ' | ' | -2,500 | -2,000 | -4,500 |
Exercised (in Dollars per share) | ' | ' | ' | $0.38 | $0.40 |
Cancelled or expired | ' | ' | ' | ' | -10,000 |
Cancelled or expired (in Dollars per share) | ' | ' | ' | ' | $0.43 |
Outstanding November 30, 2013 | ' | ' | ' | ' | 884,000 |
Outstanding November 30, 2013 (in Dollars per share) | ' | ' | ' | ' | $0.49 |
Significant_Accounting_Policie5
Significant Accounting Policies (Details) - Reconciliation of the numerators and denominators of the basic and diluted earnings per share (USD $) | 3 Months Ended | 6 Months Ended | ||
Nov. 30, 2013 | Nov. 30, 2012 | Nov. 30, 2013 | Nov. 30, 2012 | |
Numerator: | ' | ' | ' | ' |
(Loss)income from continuing operations (in Dollars) | ($243,357) | $236,919 | ($411,072) | $528,550 |
Denominator for basic net (loss) income Per common share | 7,278,967 | 6,966,185 | 7,277,659 | 6,959,224 |
Effect of dilutive securities: | ' | ' | ' | ' |
Options and warrants | ' | 418,954 | ' | 322,978 |
Denominator for diluted net (loss) income per common share | 7,278,967 | 7,385,139 | 7,277,659 | 7,282,202 |
Basic net (loss) income per common share (in Dollars per share) | ($0.03) | $0.03 | ($0.06) | $0.08 |
Diluted net (loss) income per common share (in Dollars per share) | ($0.03) | $0.03 | ($0.06) | $0.07 |
Accounts_Payable_and_Accrued_E2
Accounts Payable and Accrued Expenses (Details) - Accounts payable and accrued expense balances (USD $) | Nov. 30, 2013 | 31-May-13 |
Accounts payable and accrued expense balances [Abstract] | ' | ' |
Accounts payable | $167,810 | $282,138 |
Accrued expenses | 48,803 | ' |
Deferred rent | 63,361 | 69,779 |
Total | $279,974 | $351,917 |
Geographic_Information_Details
Geographic Information (Details) (Geographic Concentration Risk [Member], Sales Revenue, Net [Member]) | 6 Months Ended |
Nov. 30, 2013 | |
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | ' |
Geographic Information (Details) [Line Items] | ' |
Concentration Risk, Percentage | 10.00% |
Geographic_Information_Details1
Geographic Information (Details) - Geographic Information (USD $) | 3 Months Ended | 6 Months Ended | ||
Nov. 30, 2013 | Nov. 30, 2012 | Nov. 30, 2013 | Nov. 30, 2012 | |
Revenues from sales to unaffiliated customers: | ' | ' | ' | ' |
Net Sales | $934,841 | $1,883,771 | $1,948,580 | $3,585,719 |
United States [Member] | ' | ' | ' | ' |
Revenues from sales to unaffiliated customers: | ' | ' | ' | ' |
Net Sales | 251,000 | 157,000 | 505,000 | 437,000 |
Asia [Member] | ' | ' | ' | ' |
Revenues from sales to unaffiliated customers: | ' | ' | ' | ' |
Net Sales | 80,000 | 1,042,000 | 216,000 | 1,944,000 |
Europe [Member] | ' | ' | ' | ' |
Revenues from sales to unaffiliated customers: | ' | ' | ' | ' |
Net Sales | 594,000 | 675,000 | 1,199,000 | 1,183,000 |
South America [Member] | ' | ' | ' | ' |
Revenues from sales to unaffiliated customers: | ' | ' | ' | ' |
Net Sales | 4,000 | 2,000 | 7,000 | 2,000 |
Middle East [Member] | ' | ' | ' | ' |
Revenues from sales to unaffiliated customers: | ' | ' | ' | ' |
Net Sales | 5,000 | 7,000 | 20,000 | 18,000 |
Other Foreign [Member] | ' | ' | ' | ' |
Revenues from sales to unaffiliated customers: | ' | ' | ' | ' |
Net Sales | $1,000 | $1,000 | $2,000 | $2,000 |
Commitments_and_Contingencies_
Commitments and Contingencies (Details) (USD $) | 6 Months Ended | |
Nov. 30, 2013 | 31-May-13 | |
Commitments and Contingencies Disclosure [Abstract] | ' | ' |
Line of Credit Facility, Maximum Borrowing Capacity (in Dollars) | $400,000 | ' |
Line of Credit Facility, Interest Rate Description | '1.0% plus the Wall Street Journal Prime West Coast Edition prime rate | ' |
Line of Credit Facility, Expiration Date | 24-Feb-14 | ' |
Line of Credit Facility, Amount Outstanding (in Dollars) | 0 | 0 |
Lease Agreement Date | 18-Jun-09 | ' |
Lease initiation Date | 1-Sep-09 | ' |
Lease Expiration Date | 31-Aug-16 | ' |
Operating Leases, Rent Expense, Minimum Rentals (in Dollars) | 18,490 | ' |
Operating Leases, Rent Expense (in Dollars) | $20,810 | ' |